- Home
- INMB vs SRTS Comparison
INMB vs SRTS Comparison
Compare INMB & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- SRTS
- Stock Information
- Founded
- INMB 2015
- SRTS 2010
- Country
- INMB United States
- SRTS United States
- Employees
- INMB 17
- SRTS N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- INMB Health Care
- SRTS Health Care
- Exchange
- INMB Nasdaq
- SRTS Nasdaq
- Market Cap
- INMB 108.0M
- SRTS 106.0M
- IPO Year
- INMB 2019
- SRTS 2016
- Fundamental
- Price
- INMB $4.87
- SRTS $8.89
- Analyst Decision
- INMB Strong Buy
- SRTS Strong Buy
- Analyst Count
- INMB 2
- SRTS 2
- Target Price
- INMB $21.00
- SRTS $12.50
- AVG Volume (30 Days)
- INMB 239.3K
- SRTS 262.3K
- Earning Date
- INMB 10-31-2024
- SRTS 11-14-2024
- Dividend Yield
- INMB N/A
- SRTS N/A
- EPS Growth
- INMB N/A
- SRTS N/A
- EPS
- INMB N/A
- SRTS 0.57
- Revenue
- INMB $42,000.00
- SRTS $41,308,000.00
- Revenue This Year
- INMB N/A
- SRTS $55.14
- Revenue Next Year
- INMB N/A
- SRTS $21.75
- P/E Ratio
- INMB N/A
- SRTS $15.62
- Revenue Growth
- INMB N/A
- SRTS 65.62
- 52 Week Low
- INMB $4.45
- SRTS $2.05
- 52 Week High
- INMB $14.74
- SRTS $9.20
- Technical
- Relative Strength Index (RSI)
- INMB 39.31
- SRTS 75.94
- Support Level
- INMB $4.45
- SRTS $6.70
- Resistance Level
- INMB $6.26
- SRTS $9.20
- Average True Range (ATR)
- INMB 0.31
- SRTS 0.56
- MACD
- INMB -0.14
- SRTS 0.21
- Stochastic Oscillator
- INMB 19.63
- SRTS 89.08
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.